Cas12 Protein Market Report 2026

The cas12 protein market size has grown rapidly in recent years. It will grow from $2.26 billion in 2025 to $2.62 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to early adoption of crispr-cas technologies, increasing academic research in gene editing, rising demand for molecular biology tools, growth in genetic engineering studies, availability of basic cas12 protein variants.

The cas12 protein market size is expected to see rapid growth in the next few years. It will grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to expansion of crispr-based diagnostics, development of advanced delivery methods, increasing investment in gene therapies, growing pharmaceutical and biotechnology r&d spending, rising regulatory approvals for crispr-based therapeutics. Major trends in the forecast period include growing use of cas12 in rapid molecular diagnostics, rising adoption of cas12 for precise genome editing, increasing development of modified and high-fidelity cas12 variants, expansion of cas12 applications in therapeutics development, rising demand for lyophilized and stable cas12 formulations.

The increasing prevalence of genetic diseases is expected to drive the growth of the Cas12 protein market in the coming years. Genetic diseases are conditions caused by alterations or mutations in an individual’s DNA that disrupt normal physiological functions. The rising prevalence of genetic diseases is largely attributed to the increasing rate of consanguineous marriages, which elevates the risk of inheriting hereditary disorders. Cas12 protein enables precise gene-editing by targeting and cutting DNA at specific locations to correct, remove, or replace defective genes, supporting the development of accurate gene therapies for inherited conditions with minimal off-target effects. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, 2,788 patients were living with hereditary haemophilia A (HMA) during 2023-2024, an increase from 2,681 patients in 2022-2023. Therefore, the increasing prevalence of genetic diseases is driving the growth of the Cas12 protein market.

Major companies operating in the Cas12 protein market are focusing on advanced strategies, such as equity investments, to accelerate innovation and expand their gene-editing capabilities. Equity investment involves acquiring ownership stakes in companies to support growth while gaining access to proprietary technologies and future returns. For example, in April 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, invested $100 million in Mammoth Biosciences to gain access to its ultracompact CRISPR enzymes for in vivo gene-editing therapies delivered via adeno-associated viruses (AAVs) across multiple tissues beyond the liver. This collaboration combines Mammoth’s ultracompact CRISPR enzymes with advanced AAV delivery systems, enabling precise and efficient in vivo gene editing due to the enzymes’ compatibility with AAV vector size constraints. The partnership provides Mammoth with significant funding, milestone payments, and royalty opportunities, while granting Regeneron exclusive access to these technologies for over five years, collectively advancing next-generation genetic medicines for a broader range of diseases.

In August 2023, Hui-Gene Therapeutics Co., Ltd., a China-based biotechnology company, partnered with Kactus Biotechnology to develop innovative gene-editing therapies targeting rare genetic disorders. This collaboration aims to accelerate the commercialization and good manufacturing practice (GMP) production of HuidaGene’s high-precision gene-editing enzyme hfCas12Max in Greater China by leveraging Kactus Biotechnology’s expertise. Kactus Biotechnology is a China-based biotechnology company specializing in the manufacturing of Cas12 proteins.

Major companies operating in the cas12 protein market are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Aldevron LLC, New England Biolabs Inc., Synthego Corporation, Mammoth Biosciences Inc., Editas Medicine Inc., VectorBuilder, Sherlock Biosciences, Inscripta Inc.

North America was the largest region in the Cas12 protein market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cas12 protein market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cas12 protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the cas12 protein market by increasing the cost of imported enzymes, reagents, plasmids, and specialized laboratory equipment, affecting research and commercial production timelines. Genome editing and diagnostic application segments are most affected, particularly in regions such as north america and asia-pacific that rely on cross-border sourcing of biotech materials. These cost pressures have slowed adoption in some research institutes and small biotech firms. However, tariffs have also encouraged local manufacturing, regional sourcing of crispr components, and investment in domestic biotechnology capabilities.

The cas12 protein market research report is one of a series of new reports that provides cas12 protein market statistics, including cas12 protein industry global market size, regional shares, competitors with a cas12 protein market share, detailed cas12 protein market segments, market trends and opportunities, and any further data you may need to thrive in the cas12 protein industry. This cas12 protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cas12 protein is a CRISPR-associated enzyme involved in gene editing and molecular diagnostic applications. Guided by CRISPR RNA, Cas12 precisely identifies and cleaves specific DNA sequences, allowing for accurate genetic modifications. In addition, its collateral cleavage activity enables rapid and highly sensitive detection, making it valuable for diagnostic testing.

The main types of Cas12 protein include natural Cas12 proteins, modified Cas12 proteins, and Cas12 systems integrated with other CRISPR components. Natural Cas12 proteins are bacterial-derived enzymes that detect and cut specific DNA sequences as part of the CRISPR-based immune defense mechanism. These proteins are offered in multiple formulations such as liquid solutions, lyophilized powders, and plasmid-based formats, and are delivered using methods including viral vectors, lipid nanoparticles, electroporation, and microinjection. They are extensively applied in genome editing, gene knockout, gene regulation, genetic engineering, and therapeutic development, and are utilized by end users such as academic and research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and agricultural organizations.

The Cas12 protein market consists of sales of molecular diagnostic kits, research reagents, and biosensors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.